Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 21, 2026

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

View original at finance.yahoo.com

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

GLP-1 therapy sales (Mounjaro and Zepbound) are expected to remain strong throughout 2026
60% confidence
Early launch data for Foundayo has been encouraging, and insurance coverage for the pill is expanding rapidly through major pharmacy benefit managers
60% confidence
Lilly expects to launch Foundayo in most international markets during 2027
60% confidence

Data points we hold from this source

Novo Nordisk · market share

94 percent